Jeremy Grantham reported an equity portfolio valued at approximately $39.10 billion in the latest quarter, reflecting GMO's long-standing focus on high-quality businesses with durable competitive advantages and strong long-term earnings power. The portfolio remains broadly diversified across technology, healthcare, financials, and industrials, while maintaining meaningful concentration in a select group of large-cap holdings. The latest filing showed moderate activity, with several additions to core positio ...